Development and validation of a RNA binding protein gene pair-associated prognostic signature for prediction of overall survival in hepatocellular carcinoma.

Publisher: BioMed Central Country of Publication: England NLM ID: 101147518 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-925X (Electronic) Linking ISSN: 1475925X NLM ISO Abbreviation: Biomed Eng Online Subsets: MEDLINE

Original Publication: London : BioMed Central, [2002-

Gene Expression Profiling*; Carcinoma, Hepatocellular/*diagnosis ; Carcinoma, Hepatocellular/*genetics ; Liver Neoplasms/*diagnosis ; Liver Neoplasms/*genetics ; RNA-Binding Proteins/*genetics; Female ; Humans ; Male ; Middle Aged ; Prognosis ; Reproducibility of Results ; Survival Analysis

Background: Increasing evidence has demonstrated the correlation between hepatocellular carcinoma (HCC) prognosis and RNA binding proteins (RBPs) dysregulation. Thus, we aimed to develop and validate a reliable prognostic signature that can estimate the prognosis for HCC.
Methods: Gene expression profiling and clinical information of 374 HCC patients were derived from the TCGA data portal. The survival-related RBP pairs were determined using univariate cox-regression analysis and the signature was built based on LASSO analysis. All patients were divided patients into high-and low-risk groups according to the optimal cut off of the signature score determined by time-dependent receiver operating characteristic (ROC) curve analysis. The predictive value of the signature was further validated in an independent cohort.
Results: A 37-RBP pairs signature consisting of 61 unique genes was constructed which was significantly associated with the survival. The RBP-related signature accurately predicted the prognosis of HCC patients, and patients in high-risk groups showed poor survival in two cohorts. The novel signature was an independent prognostic factor of HCC in two cohorts (all P < 0.001). Furthermore, the C-index of the prognostic model was 0.799, which was higher than that of many established risk models. Pathway and process enrichment analysis showed that the 61 unique genes were mainly enriched in translation, ncRNA metabolic process, RNA splicing, RNA modification, and translational termination.
Conclusion: The novel proposed RBP-related signature based on relative expression orderings could serve as a promising independent prognostic biomarker for patients with HCC, and could improve the individualized survival prediction in HCC.

Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20297-302. (PMID: 19088191)
Aging (Albany NY). 2019 Jan 10;11(1):160-173. (PMID: 30631005)
Wiley Interdiscip Rev RNA. 2019 May;10(3):e1520. (PMID: 30479000)
Genomics. 2020 Jul;112(4):2763-2771. (PMID: 32198063)
Cell Rep. 2018 Jan 2;22(1):286-298. (PMID: 29298429)
J Cell Biochem. 2019 May;120(5):7539-7550. (PMID: 30485492)
Gastroenterology. 2009 Sep;137(3):850-5. (PMID: 19524573)
JAMA Oncol. 2017 Nov 01;3(11):1529-1537. (PMID: 28687838)
Bioinformatics. 2015 Jan 1;31(1):62-8. (PMID: 25165092)
Liver Cancer. 2018 May;7(2):179-189. (PMID: 29888207)
Lancet. 2015 Mar 14;385(9972):977-1010. (PMID: 25467588)
Nat Methods. 2013 Jun;10(6):577-83. (PMID: 23603899)
Hepatol Int. 2019 Sep;13(5):618-630. (PMID: 31321712)
Clin Transl Oncol. 2021 Feb;23(2):265-274. (PMID: 32519178)
World J Gastroenterol. 2018 Aug 14;24(30):3426-3439. (PMID: 30122881)
Sci Rep. 2017 Jul 17;7(1):5517. (PMID: 28717245)
Trends Cancer. 2017 Jul;3(7):506-528. (PMID: 28718405)
Int J Mol Med. 2003 Apr;11(4):509-13. (PMID: 12632106)
Nat Med. 2015 Nov;21(11):1350-6. (PMID: 26457759)
Cancer Manag Res. 2019 Aug 06;11:7473-7484. (PMID: 31496805)
Clin Gastroenterol Hepatol. 2011 Jan;9(1):64-70. (PMID: 20831903)
Clin Sci (Lond). 2020 Jul 31;134(14):1973-1990. (PMID: 32677671)
PeerJ. 2019 Mar 20;7:e6548. (PMID: 30918751)
Cancer Cell Int. 2019 May 21;19:138. (PMID: 31139015)
Nat Rev Genet. 2014 Dec;15(12):829-45. (PMID: 25365966)
J Cell Biochem. 2019 Jun;120(6):9117-9124. (PMID: 30582205)
iScience. 2019 Nov 22;21:706-719. (PMID: 31733516)
Genome Biol. 2020 Aug 6;21(1):195. (PMID: 32762776)
J Cancer Res Clin Oncol. 2007 Dec;133(12):929-36. (PMID: 17497168)
Gut. 2014 May;63(5):844-55. (PMID: 24531850)
J Immunol Res. 2020 Mar 7;2020:5494858. (PMID: 32211443)
Clin Exp Immunol. 2016 Jan;183(1):37-49. (PMID: 26201441)
Int J Oncol. 2016 Apr;48(4):1313-24. (PMID: 26892688)
Aging (Albany NY). 2019 Dec 2;11(23):10861-10882. (PMID: 31790363)
Acta Biochim Biophys Sin (Shanghai). 2017 May 1;49(5):383-391. (PMID: 28369267)
N Engl J Med. 2011 Sep 22;365(12):1118-27. (PMID: 21992124)
Technol Cancer Res Treat. 2010 Apr;9(2):149-59. (PMID: 20218737)
Best Pract Res Clin Gastroenterol. 2015 Dec;29(6):919-28. (PMID: 26651253)
Nat Commun. 2019 Apr 3;10(1):1523. (PMID: 30944313)
Life Sci. 2018 Jun 15;203:83-91. (PMID: 29678742)
RNA Biol. 2009 Nov-Dec;6(5):575-83. (PMID: 19875930)
Ann Surg. 2016 Jun;263(6):1112-25. (PMID: 26813914)
RNA Biol. 2009 Sep-Oct;6(4):426-33. (PMID: 19458496)

Keywords: Hepatocellular carcinoma; Overall survival; RNA binding protein; Signature

0 (RNA-Binding Proteins)

Date Created: 20200903 Date Completed: 20210716 Latest Revision: 20240801

20240801

PMC7461748

10.1186/s12938-020-00812-0

32873282